.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,057,292

« Back to Dashboard

Claims for Patent: 6,057,292

Title: Method for inhibiting growth hormone action
Abstract:Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
Inventor(s): Cunningham; Brian C. (San Bruno, CA), Lowman; Henry B. (Hercules, CA), Wells; James A. (Burlingame, CA), Clark; Ross G. (Pacifica, CA), Olson; Kenneth (Burlingame, CA), Fuh; Germaine G. (Pacifica, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:09/028,587
Patent Claims: 1. A method for inhibiting growth hormone action in a patient comprising administering to the patient an effective amount of a human growth hormone variant comprising all of the following amino acid substitutions: H18D, H21N, R167N, K168A, D171S, K172R, E174S, I179T, and further comprising a substitution at G120.

2. The method of claim 1, wherein the patient has acromegaly.

3. The method of claim 1, wherein the patient has a tumor comprising tumor cells expressing receptors that bind human growth hormone.

4. The method of claim 1, wherein the patient has diabetic retinopathy.

5. The method of claim 1 wherein the human growth hormone variant is conjugated to one or more chemical groups that increase the actual molecular weight of the human growth hormone variant to between about 40 and about 100 kilodaltons.

6. The method of claim 5 wherein said chemical group is poly(ethylene glycol).

7. The method of claim 6 where the human growth hormone variant is conjugated to between about four and about six molecules of poly(ethylene glycol).

8. The method of claim 1 wherein the substitution at G120 is selected from G120R, G120K, G120W, G120Y, G120F, G120E.

9. The method of claim 8 wherein the substitution at G120 is G120K.

10. The method of claim 9 wherein the human growth hormone variant is conjugated to one or more chemical groups that increase the actual molecular weight of the human growth hormone variant to between about 40 and about 100 kilodaltons.

11. The method of claim 10 wherein said chemical group is poly(ethylene glycol).

12. The method of claim 11 where the human growth hormone variant is conjugated to between about four and about six molecules of polyethylene glycol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc